Experimentelle und klinische Befunde mit dem Thrombinhemmer Argatroban

H. K. Breddin

doi:10.1055/s-0037-1619547

Hämostaseologie, Table of Contents

Hamostaseologie 2002; 22(03): 137-141
DOI: 10.1055/s-0037-1619547

Research Articles

Schattauer GmbH

Experimentelle und klinische Befunde mit dem Thrombinhemmer Argatroban

Experimental and clinical results with the thrombin inhibitor Argatroban

H. K. Breddin

¹International Institute of Thrombosis and Vascular Diseases, Frankfurt am Main

› Author Affiliations

Abstract

Zusammenfassung

Argatroban ist ein niedermolekularer Thrombinhemmer. Wesentliche Eigenschaften dieses synthetisch hergestellten Medikaments sind schnelles Einsetzen der antithrombotischen Wirkung, schnelles Abklingen der gerinnungshemmenden Wirkung, die Hemmung gerinnselgebundenen Thrombins und fehlende Antikörperbildung. Bei Patienten mit Niereninsuffizienz ist keine Dosisanpassung notwendig. Argatroban wird in der Leber metabolisiert. Das Ausmaß der gerinnungshemmenden Wirkung bei intravenöser Anwendung ist vorhersagbar. Argatroban ist in den USA und Kanada zur Prophylaxe und Therapie von Thrombosen bei Patienten mit heparininduzierter Thrombozytopenie (HIT) zugelassen. Außerdem ist es in den USA auch als Antikoagulans während perkutaner koronarer Interventionen bei Patienten mit HIT oder HIT in der Vorgeschichte zugelassen. Vorläufige Berichte zeigen, dass Argatroban zur Gerinnungshemmung während einer Hämodialyse und als Antikoagulans während der thrombolytischen Behandlung des Herzinfarkts eingesetzt werden kann. Zum therapeutischen Monitoring eignet sich die aPTT (aktivierte partielle Thromboplastinzeit) für niedrige und die ACT (aktivierte Gerinnungszeit) für hohe Dosen. Die ECT (Ecarin-Gerinnungszeit) erlaubt die spezifische Messung der thrombinhemmenden Wirkung.

Summary

Argatroban is the smallest anticoagulant molecule of direct thrombin inhibitors. The main attributes of this synthetic drug are its rapid onset of anti-thrombin action, the rapid reversibility of its anticoagulant effect, potent inhibition of clot-bound thrombin, the absence of antibody formation and no need for dosage adjustment in patients with renal impairment. It is eliminated by hepatic metabolism. These properties make argatroban a predictable anticoagulant with intravenous use in a routine clinical setting. Argatroban is approved in the US and Canada for both prophylaxis and treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT) and in the US as an antithrombotic agent during percutaneous coronary interventions in patients with HIT or a history of HIT. Preliminary reports document the feasibility of using argatroban for anticoagulation during hemodialysis and as adjunct to thrombolysis for treatment of myocardial infarction. Current recommendations for argatroban monitoring are to use the aPTT (activated partial thromboplastin time) for low doses and the ACT (activated clotting time) for high doses. The specific inhibition of thrombin can be measured with the ECT (ecarin clotting time).

Schlüsselwörter

Argatroban - Thrombinhemmer - heparininduzierte Thrombozytopenie - Gerinnungshemmung

Keywords

Argatroban - thrombin inhibitor - heparin-induced thrombocytopenia - coagulation inhibitor

Full Text

References

Literatur
1 Ahmad S, Ahsan A, George M. et al. Simultaneous monitoring of argatroban and its major metabolite using an HPLC method: potential clinical applications. Clin Appl Thromb Hemost 1999; 5: 252-8.
2 Amiral J, Bridey F, Dreyfus M. et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68: 95-6.
3 Banner DW, Hadvary P. Inhibitor binding to thrombin with X-ray crystallographic studies. Adv Exp Med Biol 1993; 340: 27-33.
4 Bauer M, Brandstetter H, Turk D. et al. Crystallographic determination of thrombin complexes with small synthetic inhibitors as a starting point for the receptor-based design of antithrombotics. Semin Thromb Hemost 1993; 19: 352-60.
5 Berry CN, Girardot C, Lecoffre C. et al. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemost 1994; 72: 381-6.
6 Brandt JT, Isenhart CE, Osborne JM. et al. On the role of platelet FcγRIIA phenotype in heparin-induced thrombocytopenia. Thromb Haemost 1995; 74: 1564-72.
7 Brieger DB, Mak KH, Kottke-Marchant K. et al. Heparin-induced thrombocytopenia. J Amer Coll Cardiol 1998; 31: 1449-59.
8 Bush LR. Argatroban, a selective, potent thrombin inhibitor. Cardiovasc Drug Rev 1991; 9: 247-63.
9 Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin associated thrombocytopenia. N Engl J Med 1987; 316: 581-9.
10 Clark RJ, Mayo G, Fitzgerald GA. et al. Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation 1991; 83: 1510-8.
11 Eichler P, Friesen HJ, Lubenow N. et al. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood 2000; 96: 2373-8.
12 Greinacher A, Eichler P, Lubenow N. et al. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000; 96: 846-51.
13 Greinacher A, Janssens U, Berg G. et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators. Circulation 1999; 100: 587-93.
14 Greinacher A, Michels I, Liebenhoff U. et al. Heparin-associated thrombocytopenia: Immune complexes are attached to the platelet membrane by the negative charge of highly sulphated oligosaccharides. Br J Haematol 1993; 84: 711-6.
15 Greinacher A, Pötzsch B, Amiral J. et al. Heparin-associated thrombocytopenia: Isolation of the antibody and characterization of a multimolecular PF-4 heparin complex as the major antigen. Thromb Haemost 1994; 71: 247-51.
16 Greinacher A, Volpel H, Janssens U. et al. Recombinant hirudin (lepirudin) proved safe and effective anticoagulation in patients with heparin-induced thrombocytpenia: a prospective study. Circulation 1999; 99: 73-80.
17 Hantgan RR, Jerome WG, Hursting MJ. No effect of clot age or thrombolysis on argatroban’s inhibition of thrombin. Blood 1998; 92: 2064-74.
18 Hauptmann J, Markwardt F. Pharmacological aspects of the development of selective synthetic thrombin inhibitors as anticoagulants. Sem Thromb Hemost 1992; 18: 200-17.
19 Herrman J-P, Suryapranata H, den Heijer P. et al. Argatroban during percutaneous transluminal coronary angioplasty: Results of a dose-verification study. J Thromb Thrombolysis 1996; 3: 367-75.
20 Hijikata-Okunomiya A, Okamoto S. A strategy for a rational approach to designing synthetic selective inhibitors. Semin Thromb Hemost 1992; 18: 135-49.
21 Hursting MJ, Alford KL, Becker JC. et al. Novastan (brand of argatroban): A small-molecule, direct thrombin inhibitor. Semin Thromb Hemost 1997; 23: 503-16.
22 Hursting MJ, Becker JC, Joffrion JL. et al. Effect of hepatic function on the pharmacokinetics and pharmacodynamics of argatroban. Thromb Haemost 1997; (Suppl): 493-4.
23 Hursting MJ, Joffrion JL, Brooks RL. et al. Effect of renal function on the pharmacokinetics and pharmacodynamics of argatroban (a direct thrombin inhibitor). Blood 1996; 88 (Suppl. 01) 167a.
24 Inglis AL, Sheth SB, Hursting MJ. et al. Lack of interaction between argatroban, a direct thrombin inhibitor, and three frequently prescribed medications, acetaminophen, lidocaine and digoxin. International Pharmaceutical Abstracts 2000; 37: 2271.
25 Itoh T, Nonogi H, Miyazaki S. et al. Local delivery of argatroban using drug delivery device “dispatch” in the prevention of restenosis following coronary angioplasty trial (40-CAT): Result of the prospective randomized pilot study. Circulation 1997; 96: 3635.
26 Jang I-K, Brown DF, Giugliano RP. et al. the MINT investigators. A multicenter, randomized study of argatroban versus heparin as adjunct to TPA in acute myocardial infarction: myocardial infarction with Novastan and TPA (MINT) trial. J Am Coll Cardiol 1999; 33: 1879-85.
27 Jeske W, Walenga JM, Lewis BE. et al. Pharmacology of argatroban. Exp Opin Invest Drugs 1999; 8: 625-54.
28 Kikumoto R, Tamao Y, Tezuka T. et al. Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N ²-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-L-arginyl)]-2-piperidinecarboxylic acid. Biochemistry 1984; 23: 85-90.
29 Kobayashi H, Suzuki S, Sakamoto S. et al. Argatroban, a direct thrombin inhibitor versus heparin during and after percutaneous transluminal coronary angioplasty (PTCA). Thromb Haemost 1997; (Suppl): 494.
30 Kobayashi S, Tazaki Y. Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis. Sem Thromb Hemost 1997; 23: 531-4.
31 Koide M, Yamamoto S, Matsuo M. et al. Anticoagulation for HIT with spontaneous platelet aggregation in a patient requiring haemodialysis. Nephrol Dial Transplant 1995; 10: 2137-40.
32 Lewis B, Cohen M, Moses J, Matthai W. for the ARG-216/310/311 investigators. Argatroban anticoagulation during initial and repeat percutaneous coronary intervention in patients with HIT. Am J Cardiol 2000; 86 (Suppl 8A): 141.
33 Lewis BE, Ferguson JJ, Grassman ED. et al. Successful coronary interventions performed with argatroban anticoagulation in patients with heparin-induced thrombocytopenia and thrombosis syndrome. J Invas Cardiol 1996; 8: 410-7.
34 Lewis BE, Grassman ED, Wrona L. et al. Novastan anticoagulation during renal stent implant in a patient with HIT. Blood Coagul Fibrinolysis 1997; 8: 54-8.
35 Lewis BE, Rangel Y, Fareed J. The first report of successful carotid stent implant using argatroban anticoagulation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome. Angiology 1998; 49: 61-7.
36 Lewis BE, Wallis DE, Berkowitz SD. et al. for the ARG-911 Study Investigators. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103: 1838-43.
37 Magnani HN. Einsatz von Danaparoid (Orgaran^®) zur Antikoagulation bei kardiovaskulären Operationen. VASA 2000; 29 (Suppl. 56) D02.
38 Magnani HN. Heparin-induced thrombocytopenia (HIT): An overview on 230 patients treated with orgaran (Org 10172). Thromb Haemost 1993; 70: 554-61.
39 Markwardt F. Pharmacological control of blood coagulation by synthetic low-molecular-weight inhibitors of clotting enzymes. A new concept of anticoagulants. Trends in Pharmacol Sci 1980; 1: 153-7.
40 Markwardt F. Pharmacological control of hyperproteolytic states in blood by synthetic inhibitors of serine proteinases. Haemostasis 1978; 7: 177-82.
41 Markwardt F. Die Isolierung und chemische Charakterisierung des Hirudins. Hoppe-Seyler’s Z physiol Chem 1957; 308: 147-56.
42 Matsuo T, Chikahira Y, Yamada T. et al. Effect of synthetic thrombin inhibitor (MD805) as an alternative drug on HIT during hemodialysis. Thromb Res 1988; 52: 165-71.
43 Matsuo T, Kario K, Matsuda S. et al. Effect of thrombin inhibition on patients with peripheral arterial obstructive disease:A multicenter clinical trial of argatroban. J Thromb Thrombolysis 1995; 2: 131-6.
44 Okamoto S, Hijikata A. Potent inhibition of thrombin by the newly synthesized arginine derivative no. 805. The importance of stereo-structure of its hydrophobic carboxamide portion. Biochem Biophys Res Commun 1981; 101: 440-6.
45 Okamoto S, Kinjo K, Hijikata A. Thrombin inhibitors. 1. Ester derivatives of Nα-(arylsulfonyl)-arginine. J Med Chem 1980; 23: 827-30.
46 Okamoto S, Okunomiya-Hijikata A. Synthetic selective inhibitors of thrombin. Meth Enzymol 1993; 222: 328-40.
47 Sheth SB, DiCicco RA, Hursting MJ. et al. Interpreting the International Normalized Ratio in individuals receiving argatroban and warfarin. Thromb Haemost 2001; 85: 435-40.
48 Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000; 20: 318-29.
49 Swan SK, St PJV, Lambrecht LJ, Hursting MJ. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy 2000; 20: 756-70.
50 Tatsuno J, Komatsu T, Iida S. Pharmacokinetic studies of argatroban (MD-805): Protein binding and blood cell binding. Jap Pharmacol Ther 1986; 14 (Suppl. 05) 243-9.
51 Tran JQ, DiCicco RA, Sheth SB. Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban. J Clin Pharmacol 1999; 39: 513-9.
52 Vermeer F, Vahanian A, Fels P. et al. Argatroban and alteplase in patients with acute myocardial infarction: The ARGAMI study. J Thromb Thrombolysis 2000; 10: 233-40.
53 Walenga JM, Ahmad S, Hoppensteadt D. et al. Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with HIT. Persönliche Mitteilung;
54 Walenga JM, Fasanella AR, Iqbal O. et al. Coagulation laboratory testing in patients treated with argatroban. Semin Thromb Hemost 1999; 25 (Suppl. 01) 61-6.
55 Wilde MI, Markham A. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. Drugs 1997; 54: 903-24.